NAD | Jotup

Hydreight Reports Record Topline(1) Revenue of $4.87M in Q1-2024 (YOY Increase of 33%)

Retrieved on:

木曜日, 5月 30, 2024

Nucleotide, Metabolism, Pain management, NURS, Exercise, Health, Ageing, NAD, GAAP, Nicotinamide adenine dinucleotide, LAS, Nursing, Diet, Mobile phone

Q1, 2024 GAAP revenue was $3.38 million an increase of 44% compared to Q1, 2023.

Key Points:

Q1, 2024 GAAP revenue was $3.38 million an increase of 44% compared to Q1, 2023.
Q1 2024 topline¹ record revenue of $4.87 million, an increase of 33% compared to Q1, 2023.
Shane Madden, CEO of Hydreight commented, “We had an outstanding quarter with record revenue, Adjusted EBITDA¹, Adjusted revenue¹.
Hydreight provided a corporate update reflecting significant revenue growth and strong organic operational growth.

Expert Advertising Attorney Joins Davis Wright Tremaine

Retrieved on:

火曜日, 5月 28, 2024

View the full release here: https://www.businesswire.com/news/home/20240527383329/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240527383329/en/
Wolff advises clients on issues that span the complete advertising and marketing lifecycle from concept through claims development, testing, and campaign launch.
Wolff comes to the firm from Kelley Drye & Warren LLP, where she practiced for more than 14 years and chaired the FDA practice group.
“Legal issues surrounding advertising and marketing are relevant to every industry in every geography,” said Brian Hurh, DWT’s Washington, D.C. partner-in-charge.
Said Wolff: “Davis Wright Tremaine has shown a commitment to three of the strategic objectives most important to me: great client service, purpose-driven growth, and DEI values.

Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease

Retrieved on:

木曜日, 5月 23, 2024

Targeting this pathway with an IDO-1 inhibitor hinders B cell transformation and EBV-driven pathogenesis in vitro and in animal models in vivo.

Key Points:

Targeting this pathway with an IDO-1 inhibitor hinders B cell transformation and EBV-driven pathogenesis in vitro and in animal models in vivo.
The groundbraking findings reported in Science point at IDO-1 inhibition as a potential treatment mechanism for pathologies related to EBV latency.
Professor Christoph Hess, founder and Chief Scientific Officer at Hornet Therapeutics added: “In a landmark paper published 60 years ago, Drs.
Our data demonstrate that HTX-201 has the potential to hinder EBV latency in its primary host cells, the B cells.

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Retrieved on:

木曜日, 5月 23, 2024

Women, Seniors, Men, Biotechnology, Other Health, Health, Consumer, Pharmaceutical, General Health, ChromaDex, NAD, Conference, Security (finance)

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

Key Points:

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event.
To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at 1×[email protected] or register for the event at https://lythampartners.com/spring2024invreg/ .
For additional Investor Relation information on ChromaDex, visit www.chromadex.com .

ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

Retrieved on:

水曜日, 5月 22, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce that its flagship ingredient, Niagen® (patented nicotinamide riboside, NR), the most efficient and high-quality NAD+ booster and the active ingredient in the company’s consumer supplement, Tru Niagen ®, has been awarded the NutraIngredients EU Healthy Ageing Ingredient of the Year Award .

Key Points:

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce that its flagship ingredient, Niagen® (patented nicotinamide riboside, NR), the most efficient and high-quality NAD+ booster and the active ingredient in the company’s consumer supplement, Tru Niagen ®, has been awarded the NutraIngredients EU Healthy Ageing Ingredient of the Year Award .
This recognition underscores the significant contributions Niagen has made to the field of healthy aging and its role in supporting cellular health and healthspan.
View the full release here: https://www.businesswire.com/news/home/20240522381230/en/
Niagen awarded the 2024 NutraIngredients EU Healthy Ageing Ingredient of the Year Award (Graphic: Business Wire)
Recognized globally as a benchmark for excellence, the NutraIngredients EU Awards celebrate the best innovations and cutting-edge research in the nutraceutical industry.
This Award highlights ChromaDex's dedication to pioneering NAD+ research and its commitment to providing high-quality, science-backed products.

NADclinic and Bontac Bio-Engineering (Shenzhen) Co., Ltd Announce Strategic Partnership to Evolve the Future of Global Wellness Through the Power of NAD+

Retrieved on:

金曜日, 5月 17, 2024

NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness.

Key Points:

NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness.
On 6 May 2024, Bontac Bio-Engineering (Shenzhen) Co., Ltd and NADclinic Group signed a partnership cooperation agreement, formalising their ambition to become deep strategic partners.
Nicotinamide Adenine Dinucleotide (NAD+) is a coenzyme central to metabolism that is found in all living cells.
NADclinic continues to be the benchmark brand in the NAD+ sector globally, and working closely with Bontac Bio-Engineering (Shenzhen) Co., Ltd will only amplify this.

ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement

Retrieved on:

火曜日, 4月 30, 2024

Solgar’s inaugural NAD+ supplement, Solgar Cellular Nutrition Cellular Energy , features ChromaDex’s patented nicotinamide riboside (NR) ingredient, NIAGEN® to support NAD+ levels for cellular health.

Key Points:

Solgar’s inaugural NAD+ supplement, Solgar Cellular Nutrition Cellular Energy , features ChromaDex’s patented nicotinamide riboside (NR) ingredient, NIAGEN® to support NAD+ levels for cellular health.
Solgar Cellular Energy helps renew the body’s natural ability to transform nutrients into energy – the energy cells need each day.
Solgar’s Cellular Energy supplement featuring NIAGEN NR is available as part of a suite of Cellular Nutrition products.
To read more about the science supporting NIAGEN NR visit www.chromadex.com and for more information on the Solgar Cellular Nutrition Cellular Energy product featuring NIAGEN NR, please visit www.solgar.com/cellular-nutrition .

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

Retrieved on:

木曜日, 4月 25, 2024

Vitamins, Supplements, Online Retail, Health, Retail, Specialty, Life, United, The Vitamin Shoppe, ChromaDex, Nobel Prize, Research, NAD, Gold, Science, Multimedia, Longevity, Dietary supplement

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen®, is now available at The Vitamin Shoppe retail locations nationwide and online at www.vitaminshoppe.com .

Key Points:

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen®, is now available at The Vitamin Shoppe retail locations nationwide and online at www.vitaminshoppe.com .
This retail expansion adds Tru Niagen to the shelves of 700 locations of The Vitamin Shoppe and Super Supplements, enhancing consumer access to the number one healthy-aging NAD+ supplement in the United States†.
View the full release here: https://www.businesswire.com/news/home/20240425199897/en/
Tru Niagen, the number one healthy-aging NAD+ supplement in the United States, launches at The Vitamin Shoppe (Photo: Business Wire)
“This expands the distribution of Tru Niagen to an important specialty retailer,” said Rob Fried, CEO of ChromaDex and Founder of Tru Niagen.
Muriel Gonzalez, President of The Vitamin Shoppe, commented: “From cellular health to cognitive function and mobility support, innovative products that support longevity and healthspan are in growing demand at The Vitamin Shoppe and Super Supplements.

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Retrieved on:

水曜日, 4月 24, 2024

General Health, Vitamins, Supplements, Health, Fitness & Nutrition, Pharmaceutical, ChromaDex, NAD, Research

ET to discuss its financial results for the first quarter, which ended March 31, 2024.

Key Points:

ET to discuss its financial results for the first quarter, which ended March 31, 2024.
The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
ChromaDex management will host an investor conference call to discuss the first quarter 2024 results and provide a general business update on Wednesday, May 8, at 4:30 p.m.
ET.

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

Retrieved on:

火曜日, 4月 23, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut.

Key Points:

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut.
As one of the fastest-growing retailers in the United States, Sprouts Farmers Market now offers Tru Niagen to its health-conscious consumers in more than 400 locations across 23 states.
“We are privileged to have Sprouts as the first major grocery chain to carry Tru Niagen,” said Rob Fried, CEO of ChromaDex and Founder of Tru Niagen.
Sprouts Farmers Market is known for its curated selection of healthy groceries and is a go-to destination for wellness enthusiasts and those embarking on their health and wellness journeys.